Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.
Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.
复制标题
DOI：
10.1158/1078-0432.ccr-12-1206
复制
发表时间：
2012-11-01
期刊：
影响因子：
--
通讯作者：
Crowley J
中科院分区：
文献类型：
--
作者：
Matsui S;Simon R;Qu P;Shaughnessy JD Jr;Barlogie B;Crowley J
在开始最终的III期随机试验之前，开发可靠的诊断测试来预测患者对抗癌治疗在临床终点上的反应性是非常具有挑战性的。在随机试验中开发和验证基因组签名可能是一个有前途的解决方案。需要这些特征来定量预测治疗效果程度的潜在异质性。我们提出了一个在随机试验中开发和验证基因组签名的框架。预测和预后特征的共同发展可以允许预测患者水平的生存曲线作为治疗个体患者的基本诊断工具。我们将我们的框架应用于一项大规模随机试验的基因表达微阵列数据，以确定添加沙利度胺是否能改善多发性骨髓瘤患者的生存率。结果表明，大约一半的患者对沙利度胺有反应，反应患者的平均生存率提高具有统计学意义。开发了交叉验证的患者水平生存曲线，以预测个体未来患者的生存分布，作为他们是否接受沙利度胺治疗的函数，以及关于他们的基线预后和预测特征指数。拟议的框架是迈向可靠的预测医学的重要一步。它提供了一个内部验证的机制，使用随机临床试验评估患者人群的治疗疗效，同时考虑到患者对治疗反应的异质性。它还提供了交叉验证的患者水平生存曲线，可用于为未来患者选择治疗方法。
It is highly challenging to develop reliable diagnostic tests to predict patients’ responsiveness to anticancer treatments on clinical endpoints before commencing the definitive phase III randomized trial. Development and validation of genomic signatures in the randomized trial can be a promising solution. Such signatures are required to predict quantitatively the underlying heterogeneity in the magnitude of treatment effects. We propose a framework for developing and validating genomic signatures in randomized trials. Codevelopment of predictive and prognostic signatures can allow prediction of patient-level survival curves as basic diagnostic tools for treating individual patients. We applied our framework to gene-expression microarray data from a large-scale randomized trial to determine whether the addition of thalidomide improves survival for patients with multiple myeloma. The results indicated that approximately half of the patients were responsive to thalidomide, and the average improvement in survival for the responsive patients was statistically significant. Cross-validated patient-level survival curves were developed to predict survival distributions of individual future patients as a function of whether or not they are treated with thalidomide and with regard to their baseline prognostic and predictive signature indices. The proposed framework represents an important step toward reliable predictive medicine. It provides an internally validated mechanism for using randomized clinical trials to assess treatment efficacy for a patient population in a manner that takes into consideration the heterogeneity in patients’ responsiveness to treatment. It also provides cross-validated patient-level survival curves that can be used for selecting treatments for future patients.